Our consumer is always first: We listen, display compassion, and are thoughtful. We are approachable, friendly, and helpful. We believe in simplicity. We innovate. We invent and deploy technology creatively. We are data-informed and insight focused.
How do patients afford innovative medication in emerging markets? It’s the question every Market Access launching in a new market eventually asks — usually somewhere between regulatory approval and the first sales forecast, once “the medication will be on the shelf” runs into “but will anyone actually be able to pay for it?” It’s not a cynical question. It’s the honest one. And in emerging markets, the honest answer is uncomfortable: for a large share of patients, out-of-pock
In today’s evolving and emerging healthcare landscape, access is no longer just about innovation—it’s about execution. The challenge isn’t simply creating support programs, but ensuring they are fast, compliant, and truly usable at the point of care. At MED, we’ve been quietly building toward a better model. A New Standard for Copayment Enablement Our latest development focuses on enabling sponsorships for local patient support programs in a way that removes friction—without
The "Valley of Death" is just a box with no exit. We built the door. In Pharma, 90% of the genius happens in the lab. But 90% of the failure happens on the way to the shelf. At MED, we don’t R&D new molecules. We R&D the pathway to market. We’ve heard the advice to "think outside the box" to disrupt healthcare. But when you’re dealing with the FDA, Patient Data Privacy, and complex supply chains, "outside the box" is where products go to die in regulatory limbo. We Think Insi
